{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:07:31Z","timestamp":1791925651537,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:00:00Z","timestamp":1447113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T00:00:00Z","timestamp":1447113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The rapid rise of bacterial resistance to traditional antibiotics combined with the decline in discovery of novel antibacterial agents has created a global public health crisis. Repurposing existing drugs presents an alternative strategy to potentially expedite the discovery of new antimicrobial drugs. The present study demonstrates that simvastatin, an antihyperlipidemic drug exhibited broad-spectrum antibacterial activity against important Gram-positive (including methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA)) and Gram-negative pathogens (once the barrier imposed by the outer membrane was permeabilized). Proteomics and macromolecular synthesis analyses revealed that simvastatin inhibits multiple biosynthetic pathways and cellular processes in bacteria, including selective interference of bacterial protein synthesis. This property appears to assist in simvastatin\u2019s ability to suppress production of key MRSA toxins (\u03b1-hemolysin and Panton-Valentine leucocidin) that impair healing of infected skin wounds. A murine MRSA skin infection experiment confirmed that simvastatin significantly reduces the bacterial burden and inflammatory cytokines in the infected wounds. Additionally, simvastatin exhibits excellent anti-biofilm activity against established staphylococcal biofilms and demonstrates the ability to be combined with topical antimicrobials currently used to treat MRSA skin infections. Collectively the present study lays the foundation for further investigation of repurposing simvastatin as a topical antibacterial agent to treat skin infections.<\/jats:p>","DOI":"10.1038\/srep16407","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T10:11:30Z","timestamp":1447150290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent"],"prefix":"10.1038","volume":"5","author":[{"given":"Shankar","family":"Thangamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa F. N.","family":"Abushahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha I.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago J. P.","family":"Sobreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria E.","family":"Hedrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lake N.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed N.","family":"Seleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,10]]},"reference":[{"key":"BFsrep16407_CR1","first-page":"S3","volume":"14","author":"MJ Cziraky","year":"2008","unstructured":"Cziraky, M. J., Watson, K. E. & Talbert, R. L. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14, S3\u201328, quiz S30-21 (2008).","journal-title":"J Manag Care Pharm"},{"key":"BFsrep16407_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","volume":"112","author":"Y Shitara","year":"2006","unstructured":"Shitara, Y. & Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology & therapeutics 112, 71\u2013105 (2006).","journal-title":"Pharmacology & therapeutics"},{"key":"BFsrep16407_CR3","doi-asserted-by":"publisher","first-page":"28B","DOI":"10.1016\/S0002-9149(01)01454-0","volume":"87","author":"F McTaggart","year":"2001","unstructured":"McTaggart, F. et al.Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. The American journal of cardiology 87, 28B\u201332B (2001).","journal-title":"The American journal of cardiology"},{"key":"BFsrep16407_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao, J. K. & Laufs, U. Pleiotropic effects of statins. Annual review of pharmacology and toxicology 45, 89\u2013118 (2005).","journal-title":"Annual review of pharmacology and toxicology"},{"key":"BFsrep16407_CR5","doi-asserted-by":"publisher","first-page":"e75490","DOI":"10.1371\/journal.pone.0075490","volume":"8","author":"SP Parihar","year":"2013","unstructured":"Parihar, S. P. et al.Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape. PloS one 8, e75490 (2013).","journal-title":"PloS one"},{"key":"BFsrep16407_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jit550","volume":"209","author":"SP Parihar","year":"2014","unstructured":"Parihar, S. P. et al.Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. The Journal of infectious diseases 209, 754\u2013763 (2014).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep16407_CR7","doi-asserted-by":"publisher","first-page":"656 e657","DOI":"10.1016\/j.jcrc.2010.02.013","volume":"25","author":"S Janda","year":"2010","unstructured":"Janda, S., Young, A., Fitzgerald, J. M., Etminan, M. & Swiston, J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. Journal of critical care 25, 656 e657\u2013622 (2010).","journal-title":"Journal of critical care"},{"key":"BFsrep16407_CR8","doi-asserted-by":"publisher","first-page":"e10702","DOI":"10.1371\/journal.pone.0010702","volume":"5","author":"L Bjorkhem-Bergman","year":"2010","unstructured":"Bjorkhem-Bergman, L., Bergman, P., Andersson, J. & Lindh, J. D. Statin treatment and mortality in bacterial infections-a systematic review and meta-analysis. PloS one 5, e10702 (2010).","journal-title":"PloS one"},{"key":"BFsrep16407_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/jac\/dkm496","volume":"61","author":"S Jerwood","year":"2008","unstructured":"Jerwood, S. & Cohen, J. Unexpected antimicrobial effect of statins. The Journal of antimicrobial chemotherapy 61, 362\u2013364 (2008).","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"BFsrep16407_CR10","doi-asserted-by":"publisher","first-page":"e24394","DOI":"10.1371\/journal.pone.0024394","volume":"6","author":"P Bergman","year":"2011","unstructured":"Bergman, P. et al.Studies on the antibacterial effects of statins-in vitro and in vivo. PloS one 6, e24394 (2011).","journal-title":"PloS one"},{"key":"BFsrep16407_CR11","doi-asserted-by":"publisher","first-page":"e0128098","DOI":"10.1371\/journal.pone.0128098","volume":"10","author":"TS Graziano","year":"2015","unstructured":"Graziano, T. S. et al.Statins and Antimicrobial Effects: Simvastatin as a Potential Drug against Staphylococcus aureus Biofilm. PloS one 10, e0128098 (2015).","journal-title":"PloS one"},{"key":"BFsrep16407_CR12","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1128\/AAC.01826-13","volume":"58","author":"LS Lobato","year":"2014","unstructured":"Lobato, L. S. et al.Statins increase rifampin mycobactericidal effect. Antimicrobial agents and chemotherapy 58, 5766\u20135774 (2014).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1586\/eri.13.12","volume":"11","author":"JN Pendleton","year":"2013","unstructured":"Pendleton, J. N., Gorman, S. P. & Gilmore, B. F. Clinical relevance of the ESKAPE pathogens. Expert review of anti-infective therapy 11, 297\u2013308 (2013).","journal-title":"Expert review of anti-infective therapy"},{"key":"BFsrep16407_CR14","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2174\/1381612821666150310102702","volume":"21","author":"H Mohammad","year":"2015","unstructured":"Mohammad, H., Thangamani, S. & Seleem, M. N. Antimicrobial peptides and peptidomimetics-potent therapeutic allies for staphylococcal infections. Current pharmaceutical design 21, 2073\u20132088 (2015).","journal-title":"Current pharmaceutical design"},{"key":"BFsrep16407_CR15","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2174\/1381612821666150310104416","volume":"21","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Mohammad, H., Younis, W. & Seleem, M. N. Drug repurposing for the treatment of staphylococcal infections. Current pharmaceutical design 21, 2089\u20132100 (2015).","journal-title":"Current pharmaceutical design"},{"key":"BFsrep16407_CR16","doi-asserted-by":"publisher","first-page":"e0133877","DOI":"10.1371\/journal.pone.0133877","volume":"10","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Younis, W. & Seleem, M. N. Repurposing Clinical Molecule Ebselen to Combat Drug Resistant Pathogens. PloS one 10, e0133877 (2015).","journal-title":"PloS one"},{"key":"BFsrep16407_CR17","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.2174\/1381612821666150506154434","volume":"21","author":"W Younis","year":"2015","unstructured":"Younis, W., Thangamani, S. & Seleem, M. N. Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections. Current pharmaceutical design 21, 4106\u20134111 (2015).","journal-title":"Current pharmaceutical design"},{"key":"BFsrep16407_CR18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/pr0504079","volume":"5","author":"CN Lok","year":"2006","unstructured":"Lok, C. N. et al.Proteomic analysis of the mode of antibacterial action of silver nanoparticles. Journal of proteome research 5, 916\u2013924 (2006).","journal-title":"Journal of proteome research"},{"key":"BFsrep16407_CR19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1128\/AAC.47.3.948-955.2003","volume":"47","author":"JE Bandow","year":"2003","unstructured":"Bandow, J. E., Brotz, H., Leichert, L. I., Labischinski, H. & Hecker, M. Proteomic approach to understanding antibiotic action. Antimicrobial agents and chemotherapy 47, 948\u2013955 (2003).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR20","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1128\/AAC.00078-11","volume":"55","author":"M Wenzel","year":"2011","unstructured":"Wenzel, M. et al.Proteomic signature of fatty acid biosynthesis inhibition available for in vivo mechanism-of-action studies. Antimicrobial agents and chemotherapy 55, 2590\u20132596 (2011).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1128\/AAC.01640-12","volume":"57","author":"AC Jacobs","year":"2013","unstructured":"Jacobs, A. C. et al.Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents. Antimicrobial agents and chemotherapy 57, 26\u201336 (2013).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijmm.2009.10.004","volume":"300","author":"I Chatterjee","year":"2010","unstructured":"Chatterjee, I., Neumayer, D. & Herrmann, M. Senescence of staphylococci: using functional genomics to unravel the roles of ClpC ATPase during late stationary phase. International journal of medical microbiology : IJMM 300, 130\u2013136 (2010).","journal-title":"International journal of medical microbiology : IJMM"},{"key":"BFsrep16407_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijmm.2013.11.009","volume":"304","author":"D Frees","year":"2014","unstructured":"Frees, D., Gerth, U. & Ingmer, H. Clp chaperones and proteases are central in stress survival, virulence and antibiotic resistance of Staphylococcus aureus. International journal of medical microbiology : IJMM 304, 142\u2013149 (2014).","journal-title":"International journal of medical microbiology : IJMM"},{"key":"BFsrep16407_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3201\/eid1303.060960","volume":"13","author":"CJ Graber","year":"2007","unstructured":"Graber, C. J. et al.Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerging infectious diseases 13, 491\u2013493 (2007).","journal-title":"Emerging infectious diseases"},{"key":"BFsrep16407_CR25","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1128\/JCM.00582-08","volume":"46","author":"MJ Rybak","year":"2008","unstructured":"Rybak, M. J. et al.Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). Journal of clinical microbiology 46, 2950\u20132954 (2008).","journal-title":"Journal of clinical microbiology"},{"key":"BFsrep16407_CR26","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1128\/AAC.00714-10","volume":"54","author":"JB Locke","year":"2010","unstructured":"Locke, J. B. et al.Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrobial agents and chemotherapy 54, 5352\u20135355 (2010).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR27","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.01277-13","volume":"57","author":"DM Shlaes","year":"2013","unstructured":"Shlaes, D. M., Sahm, D., Opiela, C. & Spellberg, B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother 57, 4605\u20134607 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep16407_CR28","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1128\/JB.182.18.5147-5152.2000","volume":"182","author":"EI Wilding","year":"2000","unstructured":"Wilding, E. I. et al.Essentiality, expression and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococcus aureus. Journal of bacteriology 182, 5147\u20135152 (2000).","journal-title":"Journal of bacteriology"},{"key":"BFsrep16407_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1128\/AAC.46.3.605-614.2002","volume":"46","author":"A Patrzykat","year":"2002","unstructured":"Patrzykat, A., Friedrich, C. L., Zhang, L., Mendoza, V. & Hancock, R. E. Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrobial agents and chemotherapy 46, 605\u2013614 (2002).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR30","first-page":"377","volume":"237","author":"H Ulvatne","year":"2004","unstructured":"Ulvatne, H., Samuelsen, O., Haukland, H. H., Kramer, M. & Vorland, L. H. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS microbiology letters 237, 377\u2013384 (2004).","journal-title":"FEMS microbiology letters"},{"key":"BFsrep16407_CR31","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1128\/AAC.01411-05","volume":"50","author":"EE McKee","year":"2006","unstructured":"McKee, E. E., Ferguson, M., Bentley, A. T. & Marks, T. A. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrobial agents and chemotherapy 50, 2042\u20132049 (2006).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR32","first-page":"90","volume":"18","author":"S Parashar","year":"1972","unstructured":"Parashar, S., Rao, R., Tikare, S. K. & Tikare, S. S. Chloramphenicol induced reversible bone marrow suppression. A case report. Journal of postgraduate medicine 18, 90\u201392 (1972).","journal-title":"Journal of postgraduate medicine"},{"key":"BFsrep16407_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.tim.2013.10.004","volume":"22","author":"AL DuMont","year":"2014","unstructured":"DuMont, A. L. & Torres, V. J. Cell targeting by the Staphylococcus aureus pore-forming toxins: it\u2019s not just about lipids. Trends in microbiology 22, 21\u201327 (2014).","journal-title":"Trends in microbiology"},{"key":"BFsrep16407_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2165\/00003088-199732050-00005","volume":"32","author":"H Lennernas","year":"1997","unstructured":"Lennernas, H. & Fager, G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clinical pharmacokinetics 32, 403\u2013425 (1997).","journal-title":"Clinical pharmacokinetics"},{"key":"BFsrep16407_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1473-3099(10)70053-0","volume":"10","author":"JA Otter","year":"2010","unstructured":"Otter, J. A. & French, G. L. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. The Lancet. Infectious diseases 10, 227\u2013239 (2010).","journal-title":"The Lancet. Infectious diseases"},{"key":"BFsrep16407_CR36","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1128\/AAC.00846-07","volume":"51","author":"AE Simor","year":"2007","unstructured":"Simor, A. E. et al.Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrobial agents and chemotherapy 51, 3880\u20133886 (2007).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR37","doi-asserted-by":"publisher","first-page":"e69508","DOI":"10.1371\/journal.pone.0069508","volume":"8","author":"CP Montgomery","year":"2013","unstructured":"Montgomery, C. P. et al.Local inflammation exacerbates the severity of Staphylococcus aureus skin infection. PloS one 8, e69508 (2013).","journal-title":"PloS one"},{"key":"BFsrep16407_CR38","doi-asserted-by":"publisher","first-page":"e60463","DOI":"10.1371\/journal.pone.0060463","volume":"8","author":"BK Sharma-Kuinkel","year":"2013","unstructured":"Sharma-Kuinkel, B. K., Zhang, Y., Yan, Q., Ahn, S. H. & Fowler, V. G., Jr. Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model. PloS one 8, e60463 (2013).","journal-title":"PloS one"},{"key":"BFsrep16407_CR39","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1161\/01.CIR.0000033635.42612.88","volume":"106","author":"DJ Lefer","year":"2002","unstructured":"Lefer, D. J. Statins as potent antiinflammatory drugs. Circulation 106, 2041\u20132042 (2002).","journal-title":"Circulation"},{"key":"BFsrep16407_CR40","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1210\/jc.2007-0453","volume":"92","author":"I Jialal","year":"2007","unstructured":"Jialal, I., Miguelino, E., Griffen, S. C. & Devaraj, S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. The Journal of clinical endocrinology and metabolism 92, 3136\u20133140 (2007).","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"BFsrep16407_CR41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1743-6109.2006.00141.x","volume":"14","author":"AJ Cowin","year":"2006","unstructured":"Cowin, A. J., Hatzirodos, N., Rigden, J., Fitridge, R. & Belford, D. A. Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society 14, 421\u2013426 (2006).","journal-title":"Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society"},{"key":"BFsrep16407_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1128\/CMR.18.3.521-540.2005","volume":"18","author":"B Fournier","year":"2005","unstructured":"Fournier, B. & Philpott, D. J. Recognition of Staphylococcus aureus by the innate immune system. Clinical microbiology reviews 18, 521\u2013540 (2005).","journal-title":"Clinical microbiology reviews"},{"key":"BFsrep16407_CR43","first-page":"195","volume":"24","author":"H Derici","year":"2012","unstructured":"Derici, H. et al.Simvastatin Improves Incisional Wound Healing in a Rat Model: An Experimental Study. Wounds: a compendium of clinical research and practice 24, 195\u2013200 (2012).","journal-title":"Wounds: a compendium of clinical research and practice"},{"key":"BFsrep16407_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1742-481X.2011.00888.x","volume":"9","author":"S Farsaei","year":"2012","unstructured":"Farsaei, S., Khalili, H. & Farboud, E. S. Potential role of statins on wound healing: review of the literature. International wound journal 9, 238\u2013247 (2012).","journal-title":"International wound journal"},{"key":"BFsrep16407_CR45","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1128\/AAC.02578-14","volume":"58","author":"MF Mohamed","year":"2014","unstructured":"Mohamed, M. F., Hamed, M. I., Panitch, A. & Seleem, M. N. Targeting Methicillin-Resistant Staphylococcus aureus with Short Salt-Resistant Synthetic Peptides. Antimicrobial agents and chemotherapy 58, 4113\u20134122 (2014).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR46","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1203\/PDR.0b013e3181bd5bf8","volume":"66","author":"G Liu","year":"2009","unstructured":"Liu, G., Vellucci, V. F., Kyc, S. & Hostetter, M. K. Simvastatin inhibits Candida albicans biofilm in vitro. Pediatric research 66, 600\u2013604 (2009).","journal-title":"Pediatric research"},{"key":"BFsrep16407_CR47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bjid.2015.06.001","volume":"19","author":"RS Brilhante","year":"2015","unstructured":"Brilhante, R. S. et al.Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species. The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases 19, 459\u2013465 (2015).","journal-title":"The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases"},{"key":"BFsrep16407_CR48","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1128\/AAC.01803-10","volume":"55","author":"L Huang","year":"2011","unstructured":"Huang, L., Dai, T., Xuan, Y., Tegos, G. P. & Hamblin, M. R. Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections. Antimicrobial agents and chemotherapy 55, 3432\u20133438 (2011).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR49","doi-asserted-by":"publisher","first-page":"190ra181","DOI":"10.1126\/scitranslmed.3006276","volume":"5","author":"JR Morones-Ramirez","year":"2013","unstructured":"Morones-Ramirez, J. R., Winkler, J. A., Spina, C. S. & Collins, J. J. Silver enhances antibiotic activity against gram-negative bacteria. Science translational medicine 5, 190ra181 (2013).","journal-title":"Science translational medicine"},{"key":"BFsrep16407_CR50","unstructured":"CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7. CLSI, Wayne, PA. (2007)."},{"key":"BFsrep16407_CR51","doi-asserted-by":"publisher","first-page":"11596","DOI":"10.1038\/srep11596","volume":"5","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S., Younis, W. & Seleem, M. N. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections. Scientific Reports 5, 11596 (2015).","journal-title":"Scientific Reports"},{"key":"BFsrep16407_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"W Huang da","year":"2009","unstructured":"Huang da, W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research 37, 1\u201313 (2009).","journal-title":"Nucleic acids research"},{"key":"BFsrep16407_CR53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1245\/s10434-011-1940-8","volume":"19","author":"DJ Cohen","year":"2012","unstructured":"Cohen, D. J. et al.Postoperative intraperitoneal 5-fluoro-2\u2032-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. Annals of surgical oncology 19, 478\u2013485 (2012).","journal-title":"Annals of surgical oncology"},{"key":"BFsrep16407_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1128\/AAC.31.2.213","volume":"31","author":"DL Stevens","year":"1987","unstructured":"Stevens, D. L., Maier, K. A. & Mitten, J. E. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrobial agents and chemotherapy 31, 213\u2013218 (1987).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep16407_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1086\/510396","volume":"195","author":"DL Stevens","year":"2007","unstructured":"Stevens, D. L. et al.Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. The Journal of infectious diseases 195, 202\u2013211 (2007).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep16407_CR56","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2147\/DDDT.S72129","volume":"8","author":"MF Mohamed","year":"2014","unstructured":"Mohamed, M. F. & Seleem, M. N. Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection. Drug design, development and therapy 8, 1979\u20131983 (2014).","journal-title":"Drug design, development and therapy"},{"key":"BFsrep16407_CR57","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ja.2014.142","volume":"68","author":"H Mohammad","year":"2015","unstructured":"Mohammad, H., Mayhoub, A. S., Cushman, M. & Seleem, M. N. Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant Staphylococci. The Journal of antibiotics 68, 259\u2013266 (2015).","journal-title":"The Journal of antibiotics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep16407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16407","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep16407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T13:05:04Z","timestamp":1672923904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep16407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,10]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,21]]}},"alternative-id":["BFsrep16407"],"URL":"https:\/\/doi.org\/10.1038\/srep16407","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,10]]},"assertion":[{"value":"4 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16407"}}